PKO Investment Management Joint Stock Co Buys 3,000 Shares of CVS Health Corporation $CVS

PKO Investment Management Joint Stock Co grew its position in CVS Health Corporation (NYSE:CVS) by 9.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,300 shares of the pharmacy operator’s stock after purchasing an additional 3,000 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in CVS Health were worth $2,297,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Jennison Associates LLC raised its holdings in CVS Health by 503.8% in the 1st quarter. Jennison Associates LLC now owns 1,896,341 shares of the pharmacy operator’s stock valued at $128,477,000 after acquiring an additional 1,582,257 shares during the last quarter. Cantor Fitzgerald Investment Advisors L.P. increased its stake in CVS Health by 1.6% in the second quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 409,735 shares of the pharmacy operator’s stock valued at $28,264,000 after purchasing an additional 6,615 shares during the period. Cerity Partners LLC increased its stake in CVS Health by 25.0% in the first quarter. Cerity Partners LLC now owns 648,266 shares of the pharmacy operator’s stock valued at $43,920,000 after purchasing an additional 129,535 shares during the period. Bank of New York Mellon Corp increased its stake in CVS Health by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 8,981,262 shares of the pharmacy operator’s stock valued at $608,481,000 after purchasing an additional 183,813 shares during the period. Finally, Brandywine Global Investment Management LLC increased its stake in CVS Health by 20.1% in the first quarter. Brandywine Global Investment Management LLC now owns 3,421,519 shares of the pharmacy operator’s stock valued at $231,808,000 after purchasing an additional 572,533 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Performance

Shares of CVS stock opened at $81.95 on Friday. CVS Health Corporation has a one year low of $43.56 and a one year high of $83.52. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. The company has a 50 day moving average price of $75.57 and a 200 day moving average price of $68.67. The firm has a market capitalization of $103.94 billion, a price-to-earnings ratio of 22.89, a price-to-earnings-growth ratio of 0.89 and a beta of 0.60.

CVS Health (NYSE:CVS) last announced its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The business had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. During the same period in the prior year, the firm earned $1.83 earnings per share. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be given a dividend of $0.665 per share. The ex-dividend date is Thursday, October 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.2%. CVS Health’s dividend payout ratio (DPR) is 74.30%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research note on Sunday, September 21st. Baird R W upgraded shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Cowen reiterated a “buy” rating on shares of CVS Health in a research note on Monday, August 4th. Barclays boosted their price objective on shares of CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a report on Thursday, September 4th. Finally, Morgan Stanley boosted their price objective on shares of CVS Health from $82.00 to $89.00 and gave the stock an “overweight” rating in a report on Tuesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $83.38.

Insider Buying and Selling at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the transaction, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.22% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.